MarginsXMarginsX
Home › Markets › Health Care › PRAX

Praxis Precision Medicines Inc. (PRAX)

PRAX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$310.27
-5.44% on the day
Market cap
$8.7B
Mid cap
Revenue · 2025
$0
-100.0% on 2024
Net income · 2025
-$303.3M

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1689548/000168954826000029/0001689548-26-000029-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerPRAX on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2020
SEC CIK0001689548
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$0
Net income-$303.3M
Operating income-$326.2M
Net marginNeeds revenue and net income
Operating marginOperating income not reported
Revenue growth-100.0%
Cash$357.3M
Total assets$937.9M
P/E (computed)Net income was not positive
P/S (computed)Needs market cap and revenue

Warning signs

Cash runway
13.5 months
$361.9M cash at September 30, 2026
Share count, 1 year
+11.8%
2025-10-31 to 2026-11-04 · +226.2% over 3 years
Going-concern doubt
No
10-Q filed November 9, 2026
Insider net buying, 12 months
-$44.3M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.
"Liquidity In accordance with the Financial Accounting Standards Board ( FASB ) Accounting Standards Update ( ASU ) 2014-15, Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern (Subtopic 205-40) , the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within "
10-Q 2026-11-09
Cash and burn$361.9M cash; operating cash flow -$80.4M a quarter.Report 2026-09-30
Shares outstanding27,951,553 (2026-11-04); 25,007,171 a year earlier; 128,550,152 three years earlier. 3y figure adjusted for split (1-for-15 overall).Cover page 2026-11-04
Reverse splits, 3 years1; latest 1-for-15 on 2023-11-29Source 2023-11-29
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 2 424B5 takedownsLatest 2026-01-07
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorErnst & Young LLP, Boston, Massachusetts, United States; changed auditors 1 time in 24 months8-K 4.01 2026-07-02
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $44.3M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
Not filed-$94.2M-$81.7M$361.9MNo debt tagsNeeds four quarters10-Q 2026-11-09
Q2 2026
2026-06-30
Not filed-$83.7M-$77.5M$474.8MNo debt tagsNeeds four quarters10-Q 2026-11-09
Q1 2026
2026-03-31
Not filed-$92.6M-$86.2M$536.3MNo debt tagsNeeds four quarters10-Q 2026-11-09
Q4 2025
2025-12-31
$0-$88.9M-$76.3M$357.3MNo debt tags$010-K 2026-02-19
Q3 2025
2025-09-30
$0-$73.9M-$65.1M$149.5MNo debt tags$7.5M10-Q 2025-11-05
Q2 2025
2025-06-30
$0-$71.1M-$54.7M$157.4MNo debt tags$7.8M10-Q 2025-08-04
Q1 2025
2025-03-31
$0-$69.3M-$53.0M$165.6MNo debt tags$8.1M10-Q 2025-05-02
Q4 2024
2024-12-31
$7.5M-$58.7M-$56.1M$215.4MNo debt tags$8.6M10-K 2026-02-19

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-01-07
Latest annual report10-K2026-02-19
Latest quarterly / interim10-Q2026-11-09
Latest current report8-K2026-11-12
Latest proxyDEFA14A2026-04-30

Source: SEC EDGAR submissions feed, 515 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+18.2%
1 month+34.8%
3 months-10.9%
Year to date+11.3%
1 year+84.3%
From 52-week high-15.1%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
PTGXProtagonist Therapeutics Inc.$124.83-4.67%$8.1B
SYRESpyre Therapeutics Inc.$99.37-4.45%$9.4B
SMMTSummit Therapeutics Inc. Common Stock$11.82-16.47%$9.5B
TGTXTG Therapeutics Inc.$62.76-2.71%$9.5B
ALKSAlkermes plc$46.53-1.06%$7.8B
MDGLMadrigal Pharmaceuticals Inc.$423.96-0.80%$9.8B
CORTCorcept Therapeutics Incorporated$69.22-5.10%$7.6B
RYTMRhythm Pharmaceuticals Inc.$107.48-6.56%$7.5B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier